Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.25 at Ascendiant Capital Markets

Atossa Therapeutics (NASDAQ:ATOS - Free Report) had its price objective hoisted by Ascendiant Capital Markets from $7.00 to $7.25 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Ascendiant Capital Markets also issued estimates for Atossa Therapeutics' Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.

Separately, HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a report on Wednesday, March 26th.

Atossa Therapeutics Price Performance

NASDAQ ATOS traded up $0.02 during trading hours on Monday, hitting $0.76. 371,547 shares of the company's stock traded hands, compared to its average volume of 828,602. The firm's 50-day moving average is $0.70 and its 200-day moving average is $0.98. Atossa Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.81. The company has a market capitalization of $97.68 million, a PE ratio of -3.44 and a beta of 1.46.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. Equities research analysts predict that Atossa Therapeutics will post -0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ATOS. Two Sigma Advisers LP increased its stake in Atossa Therapeutics by 214.1% during the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock worth $40,000 after purchasing an additional 28,900 shares during the period. Millennium Management LLC purchased a new stake in Atossa Therapeutics during the 4th quarter worth approximately $28,000. Bank of America Corp DE boosted its position in Atossa Therapeutics by 51.3% in the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company's stock valued at $105,000 after buying an additional 37,809 shares during the period. Northern Trust Corp increased its position in shares of Atossa Therapeutics by 7.5% during the fourth quarter. Northern Trust Corp now owns 1,025,724 shares of the company's stock worth $968,000 after acquiring an additional 71,525 shares during the period. Finally, XTX Topco Ltd raised its stake in shares of Atossa Therapeutics by 59.6% in the fourth quarter. XTX Topco Ltd now owns 79,176 shares of the company's stock valued at $75,000 after acquiring an additional 29,560 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.